Category: Therapeutic Targets

Therapeutic Targets

Out with the Old: The Mitochondrial “Picture of Health” Begins with Destruction

Therapeutic Targets

Lipid-Lowering PCSK9 Inhibitors

Therapeutic Targets

The Endocannabinoid “Brake”: Fatty Acid Amide Hydrolase

Therapeutic Targets

Dr. Kelly Heim is a pharmacologist specializing in natural products. He is Senior Scientific Director, Pharmacology & Genomics for the health care professional brands of Atrium Innovations. Dr. Heim has written and illustrated various peer-reviewed publications, including scholarly reviews and book chapters on emerging phytochemical therapies. He created Integrative Pharmacology to offer complimentary learning resources on basic and clinical pharmacology of natural products for students, scholars and practitioners in the medical and life sciences.

The information contained herein was developed independently by Dr. Heim, is for educational purposes only, and does not establish a doctor-patient relationship. Dr. Kelly Heim is an employee of Atrium Innovations Inc. however, the information provided does not purport to reflect the opinions or views of Atrium Innovations or its affiliates (including but not limited to Douglas Laboratories, Pure Encapsulations, Seroyal) in any way. This information does not substitute for standard medical care. Consult your physician for any health problems.

Category: Therapeutic Targets

Natural MAO Inhibitors

Out with the Old: The Mitochondrial “Picture of Health” Begins with Destruction

Lipid-Lowering PCSK9 Inhibitors

The Endocannabinoid “Brake”: Fatty Acid Amide Hydrolase

Natural Aromatase Inhibitors